First-line chemoimmunotherapy combinations for newly diagnosed DLBCL
| Regimen . | Study phase . | Number of patients . | Median age (range), y . | Cell of origin . | ORR/CR (%) . | PFS (%) . | OS . |
|---|---|---|---|---|---|---|---|
| TR-CHOP1 | 1b | 33 | 64 (20-86) | All DLBCL | 76/73 | 73 (2 year) | 90 (2 year) |
| T/LR-CHOP1 | 1b | 33 | 64 (20-86) | All DLBCL | 82/67 | 77 (2 year) | 94 (2 year) |
| R-CHOP3 | 3 | 202 | 69 (60-80) | All DLBCL | 82/52 | 57 (2 year) | 70 (2 year) |
| Obinutuzumab-CHOP5 | 3 | 704 | 62 (18-86) | All DLBCL | 77/57 | 73 (2 year) | 84 (2 year) |
| Ibrutinib-CHOP6 | 3 | 419 | 63 (19-88) | Non-GCB | 89/67 | 70 (2 year) | 85 (2 year) |
| LR-CHOP4 | 3 | 285 | 65 (21-82) | ABC | 91/69 | 75 (2 year) | 79 (2 year) |
| Pola-R-CHP7 | 3 | 440 | 65 (19-80) | All DLBCL | 85/78 | 77 (2 year) | 89 (2 year) |
| Regimen . | Study phase . | Number of patients . | Median age (range), y . | Cell of origin . | ORR/CR (%) . | PFS (%) . | OS . |
|---|---|---|---|---|---|---|---|
| TR-CHOP1 | 1b | 33 | 64 (20-86) | All DLBCL | 76/73 | 73 (2 year) | 90 (2 year) |
| T/LR-CHOP1 | 1b | 33 | 64 (20-86) | All DLBCL | 82/67 | 77 (2 year) | 94 (2 year) |
| R-CHOP3 | 3 | 202 | 69 (60-80) | All DLBCL | 82/52 | 57 (2 year) | 70 (2 year) |
| Obinutuzumab-CHOP5 | 3 | 704 | 62 (18-86) | All DLBCL | 77/57 | 73 (2 year) | 84 (2 year) |
| Ibrutinib-CHOP6 | 3 | 419 | 63 (19-88) | Non-GCB | 89/67 | 70 (2 year) | 85 (2 year) |
| LR-CHOP4 | 3 | 285 | 65 (21-82) | ABC | 91/69 | 75 (2 year) | 79 (2 year) |
| Pola-R-CHP7 | 3 | 440 | 65 (19-80) | All DLBCL | 85/78 | 77 (2 year) | 89 (2 year) |
CR, complete response.